Healthcare Industry News: Medrad
News Release - September 18, 2007
MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners3.0T Endorectal Coil for Prostate MR Now Available for All Three Major MR Scanner Manufacturers
WARRENDALE, Pa., Sept. 18 (HSMN NewsFeed) -- Medrad today announced the availability of the 3.0T Prostate eCoil (TM) MR Endorectal Coil compatible with magnetic resonance (MR) scanners made by Philips and Siemens. Medrad introduced the 3.0T prostate eCoil for GE scanners in 2006.
"High-resolution prostate MR imaging is important to many people, especially to the hundreds of thousands of men who are diagnosed with prostate cancer each year," said Joe Havrilla, senior vice president, Medrad MR Business Unit. "By developing the eCoil for all three major scanner platforms, we increase patient access to prostate MR, an emerging new imaging procedure for early diagnosing and staging of prostate cancer."
The 3.0T Prostate eCoil conforms to the size and shape of the prostate for consistent contact between the gland and the signal-amplifying elements of the coil. The result is small field-of-view (FOV) and high spatial resolution, sensitivity, and specificity that yield clearer pictures of the prostate. These pictures provide information needed by clinicians to diagnose and stage cancer, and also to plan and deliver targeted treatment, such as radiation therapy.
Professor Jelle Barentsz, University Medical Center -- Nijmegan, The Netherlands, has used the Medrad eCoil on a Siemens 3.0T MR scanner for several years. "Using the endorectal coil at 3.0T results in such an enormous gain in spatial resolution that accurate detection of extracapsular tumor growth, in the millimeter range, is possible," said Barentsz.
Dr. Adam J. Jung, PI Prostate Imaging Group, University of Texas Health Sciences Center San Antonio, is using the Medrad eCoil on the Philips 3.0T Achieva MR scanner. "Combined endorectal coil and phased array imaging of prostate cancer at 3.0T provides robust prostate cancer depiction with dramatically improved anatomic spatial resolution, dynamic temporal resolution, and MRS metabolite dispersion," Jung said. "The result is likely improvements to both staging and image-based management of early prostate cancer."
The Prostate eCoil is also available for 1.5T magnet strength environments and is one of Medrad's Leading Image(TM) MR Coil products.
Medrad offers more information on the Prostate eCoil on the corporate Website at http://www.Medrad.com/products/mr/mr-coils/ecoil.html.
Medrad, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, Medrad's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were $478 million. Medrad is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. Medrad is an affiliate of Bayer AG. More company information is available at www.Medrad.com.
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Medrad's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Medrad, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.